AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
28th May 2026 Uncategorised 0AstraZeneca has fired another shot in its bladder cancer competition with Merck’s Keytruda, with the FDA clearing its PD-L1 inhibitor Imfinzi, used alongside standard of care, to become the first immunotherapy combination regimen for patients with high-risk non-muscle-invasive bladder cancer.
More: AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
Source: fierce